Concepedia

Author

Marie Sjögren

Lund UniversityORCID

Also Known As

Marie Sjögren

24

Publications

306

Citations

8

H-Index

30

Concepts

All Affiliations

Lund UniversityUniversity of GothenburgSahlgrenska University HospitalUniversity of UtahSkåne University Hospital
MS

About

Marie Sjögren is an author at Lund University specializing in medicine, immunology, and health sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

174

2

Health Sciences

1

1

19

3

Social Sciences

1

1

61

4

Cell Biology

1

1

61

5

Endocrinology

1

1

19

Marie Sjögren

×

8

Publications

297

Citations

8

H-Index

YearCitations

Increased intestinal permeability and gut dysbiosis in the R6/2 mouse model of Huntington’s disease

Tiberiu Loredan Stan, Rana Soylu-Kucharz, Stephen Burleigh,

Scientific Reports

2020

94

Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice

Rana Soylu-Kucharz, Åsa Sandelius, Marie Sjögren,

Scientific Reports

2017

61

The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome

Lázaro Betancourt, Jeovanis Gil, Aniel Sánchez,

Clinical and Translational Medicine

2021

38

The human melanoma proteome atlas—Defining the molecular pathology

Lázaro Betancourt, Jeovanis Gil, Yonghyo Kim,

Clinical and Translational Medicine

2021

29

Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington’s Disease

Ana I. Duarte, Marie Sjögren, Maria S. Santos,

Scientific Reports

2018

24

Ghrelin rescues skeletal muscle catabolic profile in the R6/2 mouse model of Huntington’s disease

Marie Sjögren, Ana I. Duarte, Andrew C. McCourt,

Scientific Reports

2017

21

Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6/2 mouse model of Huntington's disease

Marie Sjögren, Rana Soylu-Kucharz, Unali Dandunna,

Neurobiology of Disease

2019

19

<sup>177</sup>Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial

Andreas Hallqvist, Elva Brynjarsdóttir, T. Krantz,

Journal of Nuclear Medicine

2025

11

Page 1